High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: A pharmacokinetic and clinical study

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 6, 2007, Pages 771-779

  Tedeschi, Alessandra ^a   Montillo, Marco ^a   Strocchi, Elena ^b   Cafro, Anna Maria ^a   Tresoldi, Elisabetta ^a   Intropido, Liliana ^a   Nichelatti, Michele ^a   Marbello, Laura ^a   Baratè, Claudia ^a   Camaggi, Carlo Maurizio ^b   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukemia; High dose idarubicin; Pharmacokinetics; Salvage regimen

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IDARUBICINOL; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BRAIN LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STANDARD; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS;

EID: 33947314607     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0332-4     Document Type: Article

References (33)

1. Hoelzer D (1993) Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am 7:139-160
2. Garcia-Manero G, Thomas DA (2001) Salvage therapy for refractory or relapsed adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 15:163-205
3. Weiss MA (1997) Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). Leukemia 11:S28-S30
4. Feldaman EJ (2000) High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia. Leuk Res 24:189-191
5. Welborn JL (1994) Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 45:341-344
6. Capizzi RL, Poole M, Cooper MR, Richards F 2nd, Stuart JJ, Jackson DV, White DR, Spurr CL, Hopkins JO, Muss HB (1984) Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase. Blood 63:694-700
7. Montillo M, Tedeschi A, Centurioni R, Leoni P (1997) Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte coloni-stimulating factor (FLAG-G-CSF). Leuk Lymphoma 25:579-583
8. Arlin Z, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, Ascensao J, Baskind P, Sullivan P, Fuhr HG (1988) Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 72:433-435
9. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M (1993) Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed adult acute lymphocytic leukemia. Cancer 72:2155-2160
10. Kantarjian HM, Walters RS, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ (1990) Mitoxantrone and high dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer 65:5-8
11. Hiddeman W, Buchner T, Heil G, Schumacher K, Diedrich H, Maschmeyer G, Ho AD, Planker M, Gerith-Stolzemburg S, Donhuijsen-Ant R (1990) Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytarabine and mitoxantrone (HAM). Leukemia 4:637-640
12. Arlin ZA, Feldman EJ, Finger LR, Ahmed T, Mittelman A, Cook P, Puccio C, Baskind P, Arnold P, RAzis ED (1991) Short course high dose mitoxantrone with high dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 5:712-714
13. Raanani P, Shpilberg O, Gillis S, Avigdor A, Hardan I, Berkowicz M, Sofer O, Lossos I, Chetrit A, Ben-Yehuda D, Ben-Bassat I (1999) Salvage therapy of refractory and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine. Leuk Res 23:695-700
14. Weiss MA, Drullinsky P, Maslak P, Scheinberg D, Golde DW (1998) A phase I trial of a single high dose of idarubicin combined with high dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Leukemia 12:865-868
15. Borchmann P, Hubel K, Schnell R, Engert A (1997) Idarubicin: a brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 35:80-83
16. Schleyer E, Kuhn S, Ruhrs H, Unterhalt M, Kaufmann CC, Kem W, Braess J, Straubel G, Hiddeman W (1996) Oral idarubicin pharmacokinetics-correlation of through level with idarubicin area under the curve. Leukemia 10:707-712
17. Camaggi CM, Strocchi E, Carisi P, Maltoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymopoulos C, Pannuti F (1992) Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chem Pharmacol 30:307-316
18. National Cancer Institute, Division of Cancer Treatment (1998) Common toxicity criteria. National Cancer Institute, Bethesda
19. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19:716-723
20. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, Ferrara F, Peta A, Ciolli S, Deplano W, Fabbiano F, Sica S, Di Raimondo F, Cascavilla N, Tabilio A, Leoni P, Invernizzi R, Baccarani M, Rotoli B, Amadori S, Mandelli F (2002) Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL-0288 randomized study. The GIMEMA group. Blood 99:863-871
21. Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, Vitale A, Specchia G, Di Raimondo F, Recchia A, Cuneo A, Mecucci C, Pane F, Saglio G, Foa R, Mandelli F (2003) Clinico-biologic features and treatment outcome of adult pro-BALL patients enrolled in the GIMEMA 0496 study absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood 102:2014-2020
22. Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M, Ganser A, Kneba M, Langer W, Lipp T, Ludwig WD, Mashmeyer G, Rieder H, Thiel E, Weiss A, Messerer D (2000) Treatment of adult ALL according to protocols of the German Multicenter Study Group for adult ALL (GMALL). Hematol Oncol Clin North Am 14:1307-1325
23. Annino L, Fazi P, Specchia G (2001) Mitoxantrone in the induction treatment of adult acute lymphoblastic leukemia: GIMEMA phase II pilot study. Hematologica 86(10 Suppl):20
24. Giona F, Annino L, Rondelli R, Arcese W, Meloni G, Testi AM, Moleti ML, Amadori S, Resegotti L, Tabilio A, LAdogana S, Fioritoni G, Camera A, Liso V, Leoni P, Mandelli F (1997) Treatment of adults with acute lymphoblastic leukemia in first bone marrow relapse. Results of the ALL R-87 protocol. Br J Haematol 97:896-903
25. Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE (2002) A single high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 95:581-587
26. Camera A, Annino L, Chiurazi F, Fazi P, Cascavilla N, Fabbiano F, Marmont F, Di Raimondo F, Recchia A, Vignetti M, Rotoli B, MAndelli F (2004) GIMEMA ALL-Rescue 97: a salvage strategy for primary refractory or relapsed adult acute lymphoblastic leukemia. Haematologica 89:145-153
27. Testi AM, Del Giudice I, Arcese W, Moleti ML, Giona F, Basso G, Biondi A, Conter V, Messina C, Rondelli R, Micozzi A, Micalizzi C, Barisone E, Locatelli F, Dini G, Arico M, Casale F, Comis M, Ladogana S, Lippi A, Mura R, Pinta MF, Santoro N, Valsecchi MG, Masera G, Mandelli F (2002) A single high dose of idarubicin combined with high-dose Ara-C for treatment of first relapse childhood 'high-risk' acute lymphoblastic leukemia: a study of the AIEOP group. Br J Haematol 118:741-747
28. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S, Giles FJ, Gaiewski J, Pierce S, Keating MJ (1999) Primary refractory and relapsed adult acute lymphoblastic leukemia, characteristics, treatment results and prognosis with salvage therapy. Cancer 86:1216-1230
29. Schimmel KJ, Richel DJ, van den Brimk RB, Guchelaar HJ (2004) Cardiotoxicitty of cytotoxic drugs. Cancer Treat Rev 30:181-191
30. Karbasian-Esfahani M, Wiernik PH, Novik Y, Paietta E, Dutcher JP (2004) Idarubicin and standard doser cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia. Cancer 101:1414-1419
31. Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF (2003) High-dose consolidation chemotherapy with idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. Bone Marrow Transplant 31:275-280
32. Berg SL, Reid J, Godwin K, Murry DJ, Poplack DG, Balis FM, Ames MM (1999) Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin and their metabolites in the nonhuman primate model. J Pediatr Hematol Oncol 21:26-30
33. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM (1990) Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res 50:6525-6528